Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: Initial manifestation of childhood-onset systemic lupus erythematosus

American Journal of Clinical Pathology

Volumn 135, Issue 3, 2011, Pages 406-416

  Muscal, Eyal ^a,c   Edwards, Rachel M ^b   Kearney, Debra L ^a   Hicks, John M ^a   Myones, Barry L ^a   Teruya, Jun ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Texas Children's Hospital   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

ADAMTS13; Antiphospholipid syndrome; Lupus anticoagulant; SLE; Systemic lupus erythematosus; Thrombotic thrombocytopenic purpura

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ACQUIRED HEMOLYTIC ANEMIA; ADOLESCENT; ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; MALE; NEPHRITIS; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; REFRACTORY ANEMIA; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; IMMUNOLOGY; METABOLISM; PATHOLOGY; ULTRASTRUCTURE;

ADAM PROTEINS; ADOLESCENT; ANTIBODIES, ANTIPHOSPHOLIPID; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; FEMALE; GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 79954441994     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP5BVL4FCLCGLU     Document Type: Article

References (39)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
2. George JN. Clinical practice: thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927-1935. (Pubitemid 43872694)
3. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730-2735.
4. Liu F, Feys HB, Dong N, et al. Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus [letter]. Thromb Haemost. 2006;95:749-750.
5. Hovinga JA, Studt JD, Alberio L, et al. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol. 2004;41:75-82. (Pubitemid 38057788)
6. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83:233-244. (Pubitemid 38955446)
7. George JN, Vesely SK, James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007;100:512-514. (Pubitemid 46707454)
8. Cerveny KC, Sawitzke AD. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? Lupus. 1999;8:477-481. (Pubitemid 29423585)
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
10. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
11. Díaz-Cremades J, Fernández-Fuertes F, Ruano JA, et al. Concurrent thrombotic thrombocytopenic purpura and antiphospholipid syndrome: a rare and severe clinical combination [letter]. Br J Haematol. 2009;147:584-585.
12. Asherson RA, Cervera R, Merrill JT, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. 2008;34:256-266.
13. 2- Glycoprotein I inhibits von Willebrand factor-dependent platelet adhesion and aggregation. Blood. 2007;110:1483-1491. (Pubitemid 47443963)
14. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-534. (Pubitemid 36890145)
15. Horton TM, Stone JD, Yee D, et al. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003;25:336-339. (Pubitemid 36506226)
16. Chintagumpala MM, Hurwitz RL, Moake JL, et al. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. J Pediatr. 1992;120:49-53.
17. Loirat C, Veyradier A, Girma JP, et al. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost. 2006;32:90-97.
18. Loirat C, Girma JP, Desconclois C, et al. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol. 2009;24:19-29.
19. McDonald V, Liesner R, Grainger J, et al. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays. Blood Coagul Fibrinolysis. 2010;21:245-250.
20. Brunner HI, Freedman M, Silverman ED. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum. 1999;42:2346-2355. (Pubitemid 30333415)
21. Chak WK, Lam DS, Lo WH, et al. Thrombotic thrombocytopenic purpura as a rare complication in childhood systemic lupus erythematosus: case report and literature review. Hong Kong Med J. 2003;9:363-368. (Pubitemid 37247863)
22. Mannucci PM, Vanoli M, Forza I, et al. von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica. 2003;88:914-918. (Pubitemid 37128091)
23. Amoura Z, Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum. 2004;50:3260-3264. (Pubitemid 39372003)
24. Austin SK, Starke RD, Lawrie AS, et al. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol. 2008;141:536-544. (Pubitemid 351550559)
25. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106:1262-1267. (Pubitemid 41129589)
26. Letchumanan P, Ng HJ, Lee LH, et al. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009;48:399-403.
27. Kwok SK, Ju JH, Cho CS, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus. 2009;18:16-21.
28. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594. (Pubitemid 28536133)
29. Miyata T, Kokame K, Banno F. Measurement of ADAMTS13 activity and inhibitors. Curr Opin Hematol. 2005;12:384-389. (Pubitemid 41284973)
30. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584. (Pubitemid 28536132)
31. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47:434-444. (Pubitemid 34856134)
32. Hahn BH. Antibodies to DNA. N Engl J Med. 1998;338:1359-1368. (Pubitemid 28216666)
33. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update: on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185-1190.
34. Gungor T, Furlan M, Lammle B, et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology (Oxford). 2001;40:940-942. (Pubitemid 32816068)
35. Miyamura T, Watanabe H, Takahama S, et al. Thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus [in Japanese]. Nihon Rinsho Meneki Gakkai Kaishi. 2008;31:159-165.
36. Maruoka H, Koga T, Inoue Y, et al. Recurrent thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus. Mod Rheumatol. 2007;17:426-428. (Pubitemid 47593494)
37. Moore JC, Hayward CP, Warkentin TE, et al. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001;98:1842-1846.
38. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998;28:1-19. (Pubitemid 28378079)
39. Hamasaki K, Mimura T, Kanda H, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol. 2003;22:355-358. (Pubitemid 37483638)